Clopidogrel, genetics, and drug responsiveness

N Engl J Med. 2009 Jan 22;360(4):411-3. doi: 10.1056/NEJMe0810513.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acute Coronary Syndrome / therapy*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Cardiovascular Diseases
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Humans
  • Mutation
  • Myocardial Infarction / therapy*
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Polymorphism, Genetic
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacology
  • Ticlopidine / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine